Titre:oncodesign – biopharmaceutical company – oncology and non-oncology
La description :-- -- fr en jp news careers contact us menu about offerings innovation model technologies investors [press release] oncodesign: very strong revenue growth of 58% to €9.2 million in the first half of 2...
Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations.
Notre service GeoIP a trouvé l'hôte oncodesign.com.Actuellement, hébergé dans Italy et son fournisseur de services est IUNET BNET .
Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.
Expires:
Sat, 15 Sep 2018 13:14:43 GMT
X-Powered-By:
PHP/7.0.30
Transfer-Encoding:
chunked
Set-Cookie:
SERVERID31396=2340223; path=/; max-age=900
Content-Encoding:
gzip
Server:
Apache
Last-Modified:
Sat, 15 Sep 2018 12:14:43 GMT
Connection:
keep-alive
Pragma:
no-cache
Cache-Control:
no-cache, max-age=3600
Date:
Sat, 15 Sep 2018 12:14:43 GMT
P3P:
CP="NOI ADM DEV PSAi COM NAV OUR OTRo STP IND DEM"
MX preference = 30, mail exchanger = smtp2.oncodesign.com. MX preference = 20, mail exchanger = smtp1.oncodesign.com.
HtmlToText
-- -- fr en jp news careers contact us menu about offerings innovation model technologies investors [press release] oncodesign: very strong revenue growth of 58% to €9.2 million in the first half of 2018 - service revenue up 63.2% to €8.7 million, including robust momentum in the north american business (growth of 254%) - teams from the françois hyafil research center and bertin pharma’s service activities successfully integrated read the press release discover innovative new therapies against cancer and serious illnesses with unmet medical needs access our innovation platform via three offerings: as a service , under a partnership or based on a licensing arrangement discover our offerings our unique, patient-centered innovation model thanks to its precision medicine platform, oncodesign is able to orient at a very early stage its research and the development of innovative therapeutic solutions for resistant and unresponsive diseases explore our model a continuum of technologies from the molecule to the patient for over 20 years, oncodesign has invested in translational research technologies to bring valuable innovation into the initial phases of the drug discovery process. discover our technologies about oncodesign read our vision management introduce our management key figures see our figures discover our sab discover our mission oncodesign in the world find us offerings service starting out from your targets or your molecules, we design and select the best drug candidates idds (integrated drug discovery services) proof of concept - pharmacology dmpk bioanalysis biobanking translational biomarkers biodecontamination / biosafety partnership use our development programs at a very early stage by entering into a long-term strategic partnership kinase inhibitor development programs technology partnership licensing license technologies, drug candidates and radiotracers from oncodesign’s portfolio kinase inhibitors in oncology, cns and inflammation technologies therapeutic areas & experimental models our innovation model etiology knowledge: identifying is a big step towards solving puzzles discovery investigation: the quest for efficacy experimentation potential: formulate new treatments technologies nanocyclix® the power and selectivity of nanocyclix® molecules applied to the entire kinome. learn more t.o.t® streamline the choice of therapeutic orientation for your projects by qualifying in vitro the potential of your molecules and your targets. learn more predict® select the best drug candidates and their biomarkers by harnessing our pharmacological expertise. learn more chi-mice® use our humanized models to reproduce the targeted pathology effectively: pdx, in vivo humanization of tissues from human stem cells (liver, immune system, skin, stroma, etc.). learn more pharmimage® integrate our multi-modal pharmaco-imaging expertise with your preclinical and clinical projects. learn more oncosnipe® set the direction at a very early stage for the research and development of therapeutic solutions for resistant and unresponsive patients. learn more oncodesign news [congress] discovery on target – 25-28 september – boston - usa interested in next generation of kinase inhibitors, integrated drug discovery partner or services using our technological platforms? learn more [congress] europdx workshop - 1-3 october 2018 - weggis - switzerland join caroline mignard at the europdx workshop for great talks and discussions on all aspects of patient-derived xenograft tumor research! learn more [congress] eanm' - 13-17 october 2018 - düsseldorf - germany the eanm annual meeting is the leading conference to network and discuss the newest trends and findings in the field of nuclear medicine. learn more [press release] oncodesign furthers its cooperation with eisai, started 12 years ago 06/09/2018 learn more see all news investors financial calendar stock price documentation press releases subscribe to the investor alert investors contacts word from the chairman since our april 2014 ipo, we have accelerated our development and have become an international biopharma company specialized in precision medicine pursuing ambitious development objectives underpinned by acquisition-led growth and investments in innovative therapeutic research programs. learn more careers oncodesign’s mission is to discover innovative new therapies effective against cancer and serious illnesses with unmet medical needs. oncodesign has opted to take the time to build up all the dimensions of its organization—scientific, technical, business, starting with the most crucial one, the human dimension . our values job offers/work-study arrangements internship available spontaneous applications contact us select a service (*) sales & marketing bu finance & shareholders relationship bu press relation bu administrative bu human resources bu invalid input (*) invalid input (*) invalid input (*) please write a subject for your message. (*) please let us know your message. send sales team if you have any questions, please contact the member of our sales team responsible for your geographical region, and we will get back to you as swiftly as we can. connect with us now about oncodesign vision our mission key figures management scientific advisory board where to find us offerings services partnerships licensing therapeutic areas & experimental models our innovation model etiology discovery experimentation our technologies nanocyclix® t.o.t.® predict® chi-mice® pharmimage® oncosnipe® investors a word from the chairman financial calendar shares documentation sign up for email alerts investors contacts carreers our values job offers/work-study arrangements internships spontaneous applications news upcoming events webinars scientific publications contact contact us sales team cookies legal notice contact us (c) copyright oncodesign - all right reserved 20 rue jean mazen | b.p. 27627 | 21076 dijon cedex | france | tel.+33 (0)3.80.78.82.60 | fax +33 (0)3.80.78.82.61 newsletter- en subscribe to the general newsletter (*) invalid input (*) invalid input sign-up subscribe to the investor alert by closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them. i agree! learn more
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
"For more information on Whois status codes, please visit https://www.icann.org/resources/pages/epp-status-codes-2014-06-16-en."
% Database of ".com", ".net" domains registered by % Orange. % % Access and use restricted pursuant to french law on personal data. % % The data in this record is provided for informational purposes only as % communicated by the Domain Name Owner, and Orange does not % guarantee its accuracy. % % You agree that you will use this data only for lawful purposes and that, % under no circumstances will you use this data to allow, enable or % otherwise support any marketing activities, regardless of the medium % used. Such media include but are not limited to e-mail, facsimile, % postal mail, SMS and wireless alerts. % % You will not either sell or redistribute the data except insofar as % it has been incorporated by yourself into a value-added product or % service that does not permit the extraction of a substantial portion of % the bulk data from the value-added product or service for use by other % parties. % % % Base de donnees des domaines ".com", ".net" enregistres % par le Bureau d'Enregistrement ORANGE. % % Acces et utilisation soumis a la legislation francaise sur les donnees % personnelles. % % Ce service est fourni uniquement a titre indicatif d'apres les % declarations du titulaire du nom de domaine et Orange n'en % garantit pas l'exactitude. % % Vous acceptez de n'utiliser ces informations qu'a des fins % strictement legales et ne pourrez en permettre, faciliter ou encourager % en aucune maniere tout usage marketing, quel que soit le support utilise. % De tels supports comprennent, sans s'y limiter : l'Email, le telephone, % le FAX, le courrier postal, les SMS ou autres notifications sans fil, etc % % Vous n'etes pas non plus autorise a vendre ou redistribuer les % donnees, sauf dans le cas ou vous les avez incorporees dans un produit % ou service a valeur ajoutee qui interdise toute extraction substantielle % a fins d'utilisation par des tiers.
Nous utilisons des cookies pour personnaliser votre expérience sur notre site. En poursuivant votre navigation, vous acceptez cette utilisation. Apprendre encore plus
oncodesign.com rapport :
Visitez le site